

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

74-971

CHEMISTRY REVIEW(S)

OFFICE OF GENERIC DRUGS

ABBREVIATED NEW DRUG APPLICATION
CHEMISTRY, MANUFACTURING AND CONTROLS REVIEW

1. CHEMISTRY REVIEW NO. 4 (four)

2. ANDA #74-971

3. NAME AND ADDRESS OF APPLICANT

Novopharm Limited
Attention to: Dietrich Bartel
5691 Main Street West
Stouffville, Ontario, Canada L4A 1H5

4. LEGAL BASIS FOR SUBMISSION

The listed reference product is Nizoral® Tablets, 200mg
Manufactured by Janssen Pharmaceutica. Nizoral® is covered by US
patent (US patent no.4,335,125). The patent will expire on
06/15/1999. Novopharm's Ketoconazole tablets, 200mg will not be
made available for sale until the expiration of US patent on
06/15/99.

5. SUPPLEMENT(s)

None

6. PROPRIETARY NAME

None

7. NONPROPRIETARY NAME

Ketoconazole Tablets

8. SUPPLEMENT(s) PROVIDE(s) FOR:

None

9. AMENDMENTS AND OTHER DATES:

Major amendment: Nov 12, 1997

Minor amendment: Jul 21, 1998

telephone amendment: August 31, 1998

telephone amendments: Sept 15, and Sept 23, 1998

telephone amendment: March 15, 1999

10. PHARMACOLOGICAL CATEGORY

Antifungal

11. Rx or OTC

Rx

12. RELATED IND/NDA/DMF(s)

DMF#(type)Product

DMF holder

LOA

Seal liner

13. DOSAGE FORM


Tablets

14. POTENCY

200mg

15. CHEMICAL NAME AND STRUCTURE

Ketoconazole. $C_{26}H_{28}Cl_2N_4O_4$. 531.44. Piperazine, 1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazole-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, cis-. 65277-42-1. Antifungal. USP 23, page 864.



16. RECORDS AND REPORTS

None

17. COMMENTS

There ~~are~~ no further changes. The product was tentatively approved by FDA (October 14, 1998). EER and DMF remain acceptable.

18. CONCLUSIONS AND RECOMMENDATIONS

The application is approvable.

19. REVIEWER: DATE COMPLETED:

Liang-Lii Huang, Ph.D. May 19, 1999

Endorsed by: Paul Schwartz, Ph.D./ May 19, 1999

CC:

Endorsements:

CHEMISTRY REVIEW - APPROVABLE

OFFICE OF GENERIC DRUGS

ABBREVIATED NEW DRUG APPLICATION
CHEMISTRY, MANUFACTURING AND CONTROLS REVIEW

1. CHEMISTRY REVIEW NO. 4 (four)
2. ANDA #74-971
3. NAME AND ADDRESS OF APPLICANT

Novopharm Limited
Attention to: Dietrich Bartel
5691 Main Street West
Stouffville, Ontario, Canada L4A 1H5

4. LEGAL BASIS FOR SUBMISSION

The listed reference product is Nizoral® Tablets, 200mg
Manufactured by Janssen Pharmaceutica. Nizoral® is covered by US
patent (US patent no.4,335,125). The patent will expire on
06/15/1999. Novopharm's Ketoconazole tablets, 200mg will not be
made available for sale until the expiration of US patent on
06/15/99.

5. SUPPLEMENT(s)

None

6. PROPRIETARY NAME

None

7. NONPROPRIETARY NAME

Ketoconazole Tablets

8. SUPPLEMENT(s) PROVIDE(s) FOR:

None.

9. AMENDMENTS AND OTHER DATES:

Major amendment: Nov 12, 1997
Minor amendment: Jul 21, 1998
telephone amendment: August 31, 1998
telephone amendments: Sept 15, and Sept 23, 1998
telephone amendment: March 15, 1999

10. PHARMACOLOGICAL CATEGORY

Antifungal

11. Rx or OTC

Rx

12. RELATED IND/NDA/DMF(s)

DMF#(type)Product

DMF holder

LOA

Seal liner

13. DOSAGE FORM


Tablets

14. POTENCY

200mg

15. CHEMICAL NAME AND STRUCTURE

Ketoconazole. $C_{26}H_{28}Cl_2N_4O_4$. 531.44. Piperazine, 1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazole-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, cis-. 65277-42-1. Antifungal. USP 23, page 864.



16. RECORDS AND REPORTS

None

17. COMMENTS

There are no further changes. The product was tentatively approved by FDA (October 14, 1998). EER and DMF remain acceptable.

18. CONCLUSIONS AND RECOMMENDATIONS

The application is approvable.

19. REVIEWER: DATE COMPLETED:

Liang-Lii Huang, Ph.D. May 19, 1999

Endorsed by: Paul Schwartz, Ph.D./ May 19, 1999

cc:

1

Endorsements:

CHEMISTRY REVIEW - APPROVABLE

OFFICE OF GENERIC DRUGS

ABBREVIATED NEW DRUG APPLICATION
CHEMISTRY, MANUFACTURING AND CONTROLS REVIEW

1. CHEMISTRY REVIEW NO. 3 (three)

2. ANDA # 74-971

3. NAME AND ADDRESS OF APPLICANT

Novopharm Limited
Attention to: Dietrich Bartel
5691 Main Street West
Stouffville, Ontario, Canada L4A 1H5

4. LEGAL BASIS FOR SUBMISSION

The listed reference product is Nizoral® Tablets, 200mg
Manufactured by Janssen Pharmaceutica. Nizoral® is covered by US
patent (US patent no.4,335,125). The patent will expire on
06/15/1999. Novopharm's Ketoconazole tablets, 200mg will not be
made available for sale until the expiration of US patent on
06/15/99.

5. SUPPLEMENT(s)

None

6. PROPRIETARY NAME

None

7. NONPROPRIETARY NAME

Ketoconazole Tablets

8. SUPPLEMENT(s) PROVIDE(s) FOR:

None

9. AMENDMENTS AND OTHER DATES:

Major amendment: Nov 12, 1997
Minor amendment: Jul 21, 1998
telephone amendment: August 31, 1998
telephone amendments: Sept 15, and Sept 23, 1998

10. PHARMACOLOGICAL CATEGORY

Antifungal

11. Rx or OTC

Rx

12. RELATED IND/NDA/DMF(s)

DMF#(type)ProductDMF holderLOA

Seal liner

13. DOSAGE FORM


Tablets

14. POTENCY

200mg

15. CHEMICAL NAME AND STRUCTURE

Ketoconazole. $C_{26}H_{28}Cl_2N_4O_4$. 531.44. Piperazine, 1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazole-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, cis-. 65277-42-1. Antifungal. USP 23, page 864.

16. RECORDS AND REPORTS

None

17. COMMENTS

This application is approvable.

18. CONCLUSIONS AND RECOMMENDATIONS

The application is approvable.

19. REVIEWER: DATE COMPLETED:

Liang-Lii Huang, Ph.D. September 25, 1998

Endorsed by: Paul Schwartz, Ph.D./September 25, 1998

Page(s) 17

Contain Trade Secret,

Commercial/Confidential

Information and are not

releasable.

9/25/98

Chemistry Review 3